COVID-19: CDC, FDA and CMS Guidance
This page includes AHA Today stories and other AHA content on coronavirus COVID-19 guidance from the CDC, FDA, and CMS.
Centers for Disease Control and Prevention Director Rochelle Walensky, M.D., recommended a single COVID-19 vaccine booster dose at least six months after completing an initial mRNA COVID-19 vaccine series for certain individuals at risk for severe COVID-19, as proposed by her agency’s Advisory…
The Food and Drug Administration authorized administering a single booster dose of the Moderna and Johnson & Johnson COVID-19 vaccines to eligible individuals, and authorized eligible recipients of all three authorized COVID-19 vaccines to receive a different COVID-19 vaccine for their initial…
The Centers for Disease Control and Prevention’s Advisory Committee on Immunization Practices voted unanimously to recommend a single COVID-19 vaccine booster dose at least six months after completing an initial mRNA COVID-19 vaccine series, in the same risk groups for whom CDC recommended a Pfizer…
A mix-and-match vaccine regimen is permissible for international travelers entering the U.S., according to updated Centers for Disease Control and Prevention guidance.
Two doses of the Pfizer vaccine are 93% effective at preventing COVID-19 hospitalization among children aged 12 to 18, according to a study at 19 pediatric hospitals released by the Centers for Disease Control and Prevention.
The Centers for Disease Control and Prevention updated the list of underlying medical conditions that put adults of any age at higher risk for severe COVID-19 based on the latest scientific evidence.
Abbott Molecular Inc. issued a recall for its Alinity m SARS-CoV-2 AMP Kits and Alinity m Resp-4-Plex AMP Kits, distributed between May 13, 2020, and Aug. 31, 2021, for their potential to give false positive results.
The Centers for Disease Control and Prevention released an operational planning guide for pediatric COVID-19 vaccination and preliminary information on the pediatric Pfizer COVID-19 vaccine.
Available data support the safety and effectiveness of the Johnson & Johnson COVID-19 vaccine for emergency use authorization as a booster dose in individuals aged 18 and older at least two months after an initial single dose, the Food and Drug Administration’s Vaccines and Related Biological…
A Food and Drug Administration advisory panel voted unanimously to recommend an extra Moderna booster dose for certain individuals.